Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
Xiran He, Yang Du, Zhijie Wang, Xin Wang, Jianchun Duan, Rui Wan, Jiachen Xu, Pei Zhang, Di Wang, Yanhua Tian, Jiefei Han, Kailun Fei, Hua Bai, Jie Tian, Jie Wang, Xiran He, Yang Du, Zhijie Wang, Xin Wang, Jianchun Duan, Rui Wan, Jiachen Xu, Pei Zhang, Di Wang, Yanhua Tian, Jiefei Han, Kailun Fei, Hua Bai, Jie Tian, Jie Wang
Abstract
Background: The survival benefits of combining chemotherapy (at the maximum tolerated dose, MTD) with concurrent immunotherapy, collectively referred to as chemoimmunotherapy, for the treatment of squamous cell lung carcinoma (SQCLC) have been confirmed in recent clinical trials. Nevertheless, optimization of chemoimmunotherapy in order to enhance the efficacy of immune checkpoint inhibitors (ICIs) in SQCLC remains to be explored.
Methods: Cell lines, syngeneic immunocompetent mouse models, and patients' peripheral blood mononuclear cells were used in order to comprehensively explore how to enhance ectopic lymphoid-like structures (ELSs) and upregulate the therapeutic targets of anti-programmed death 1 (PD-1)/anti-PD-1 ligand (PD-L1) monoclonal antibodies (mAbs), thus rendering SQCLC more sensitive to ICIs. In addition, molecular mechanisms underlying optimization were characterized.
Results: Low-dose chemotherapy contributed to an enhanced antigen exposure via the phosphatidylinositol 3-kinase/Akt/transcription factor nuclear factor kappa B signaling pathway. Improved antigen uptake and presentation by activated dendritic cells (DCs) was observed, thus invoking specific T cell responses leading to systemic immune responses and immunological memory. In turn, enhanced antitumor ELSs and PD-1/PD-L1 expression was observed in vivo. Moreover, upfront metronomic (low-dose and frequent administration) chemotherapy extended the time window of the immunostimulatory effect and effectively synergized with anti-PD-1/PD-L1 mAbs. A possible mechanism underlying this synergy is the increase of activated type I macrophages, DCs, and cytotoxic CD8+ T cells, as well as the maintenance of intestinal gut microbiota diversity and composition. In contrast, when combining routine MTD chemotherapy with ICIs, the effects appeared to be additive rather than synergistic.
Conclusions: We first attempted to optimize chemoimmunotherapy for SQCLC by investigating different combinatorial modes. Compared with the MTD chemotherapy used in current clinical practice, upfront metronomic chemotherapy performed better with subsequent anti-PD-1/PD-L1 mAb treatment. This combination approach is worth investigating in other types of tumors, followed by translation into the clinic in the future.
Keywords: combination; drug therapy; immunotherapy; lung neoplasms; lymphocytes; translational medical research; tumor-infiltrating.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Bertaglia V, Vallone S, Pacchiana MV, et al. . Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. Lung Cancer Manag 2017;6:93–107. 10.2217/lmt-2017-0011
- Bunn PA. Karnofsky Award 2016: a lung cancer journey, 1973 to 2016. J Clin Oncol 2017;35:243–52. 10.1200/JCO.2016.70.4064
- Schiller JH, Harrington D, Belani CP, et al. . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–8. 10.1056/NEJMoa011954
- Cheng H, Shcherba M, Kandavelou K, et al. . Emerging drugs for squamous cell lung cancer. Expert Opin Emerg Drugs 2015;20:149–60. 10.1517/14728214.2015.1001365
- Lazzari C, Karachaliou N, Gregorc V, et al. . Second-Line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Rev Respir Med 2017;11:469–79. 10.1080/17476348.2017.1326822
- Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J Exp Med 2019;216:1244–54. 10.1084/jem.20182395
- Heinhuis KM, Ros W, Kok M, et al. . Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 2019;30:219–35. 10.1093/annonc/mdy551
- Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev 2019;290:6–23. 10.1111/imr.12766
- Paz-Ares L, Luft A, Vicente D, et al. . Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:2040–51. 10.1056/NEJMoa1810865
- Jotte RM, Cappuzzo F, Vynnychenko I, et al. . IMpower131: primary pfs and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. JCO 2018;36:LBA9000 10.1200/JCO.2018.36.18_suppl.LBA9000
- Peters S, Reck M, Smit EF, et al. . How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann Oncol 2019;30:884–96. 10.1093/annonc/mdz109
- Mathios D, Kim JE, Mangraviti A, et al. . Anti-Pd-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 2016;8:370ra180. 10.1126/scitranslmed.aag2942
- Galluzzi L, Buqué A, Kepp O, et al. . Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015;28:690–714. 10.1016/j.ccell.2015.10.012
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin 2019;69:7–34. 10.3322/caac.21551
- Shafique M, Tanvetyanon T. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther 2019;19:225–32. 10.1080/14712598.2019.1571036
- Nosaki K, Saka H, Hosomi Y, et al. . Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019;135:188–95. 10.1016/j.lungcan.2019.07.004
- Okita R, Yukawa T, Nojima Y, et al. . Mhc class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer. Cancer Immunol Immunother 2016;65:499–509. 10.1007/s00262-016-1814-9
- Zheng H, Zeltsman M, Zauderer MG, et al. . Chemotherapy-Induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 2017;9:913–27. 10.2217/imt-2017-0052
- de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-Induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 2014;20:5384–91. 10.1158/1078-0432.CCR-14-1298
- Cullis J, Siolas D, Avanzi A, et al. . Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res 2017;5:182–90. 10.1158/2326-6066.CIR-16-0125
- Liu WM, Fowler DW, Smith P, et al. . Pre-Treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010;102:115–23. 10.1038/sj.bjc.6605465
- Galluzzi L, Humeau J, Buqué A, et al. . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 2020:bbaa184. 10.1038/s41571-020-0413-z
- Pfirschke C, Engblom C, Rickelt S, et al. . Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016;44:343–54. 10.1016/j.immuni.2015.11.024
- Song W, Shen L, Wang Y, et al. . Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun 2018;9:2237. 10.1038/s41467-018-04605-x
- Weir GM, Hrytsenko O, Stanford MM, et al. . Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology 2014;3:e953407. 10.4161/21624011.2014.953407
- Denies S, Cicchelero L, Van Audenhove I, et al. . Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release 2014;187:175–82. 10.1016/j.jconrel.2014.05.045
- Liu X, Pu Y, Cron K, et al. . Cd47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015;21:1209–15. 10.1038/nm.3931
- Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197–218. 10.1038/s41573-018-0007-y
- Serrano-Del Valle A, Anel A, Naval J, et al. . Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol 2019;7:50. 10.3389/fcell.2019.00050
- Caamaño J, Hunter CA. Nf-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002;15:414–29. 10.1128/CMR.15.3.414-429.2002
- Jin X, Ding D, Yan Y, et al. . Phosphorylated Rb promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression. Mol Cell 2019;73:22–35. e26. 10.1016/j.molcel.2018.10.034
- Ramakrishnan SK, Zhang H, Ma X, et al. . Intestinal non-canonical NFκB signaling shapes the local and systemic immune response. Nat Commun 2019;10:660. 10.1038/s41467-019-08581-8
- Constantino J, Gomes C, Falcão A, et al. . Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res 2017;65:798–810. 10.1007/s12026-017-8931-1
- Pandolfi F, Altamura S, Frosali S, et al. . Key role of dAMP in inflammation, cancer, and tissue repair. Clin Ther 2016;38:1017–28. 10.1016/j.clinthera.2016.02.028
- Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Faseb J 2008;22:659–61. 10.1096/fj.07-9574LSF
- Laksono BM, de Vries RD, Verburgh RJ, et al. . Studies into the mechanism of Measles-associated immune suppression during a measles outbreak in the Netherlands. Nat Commun 2018;9:4944. 10.1038/s41467-018-07515-0
- Gridelli C, Gallo C, Di Maio M, et al. . A randomised clinical trial of two docetaxel regimens (Weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. the distal 01 study. Br J Cancer 2004;91:1996–2004. 10.1038/sj.bjc.6602241
- Di Maio M, Perrone F, Chiodini P, et al. . Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25:1377–82. 10.1200/JCO.2006.09.8251
- Voorwerk L, Slagter M, Horlings HM, et al. . Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the tonic trial. Nat Med 2019;25:920–8. 10.1038/s41591-019-0432-4
- Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 2017;17:271–85. 10.1038/nrc.2017.13
- Dzutsev A, Goldszmid RS, Viaud S, et al. . The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015;45:17–31. 10.1002/eji.201444972
- Iida N, Dzutsev A, Stewart CA, et al. . Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967–70. 10.1126/science.1240527
- Vétizou M, Pitt JM, Daillère R, et al. . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079–84. 10.1126/science.aad1329
- Sivan A, Corrales L, Hubert N, et al. . Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084–9. 10.1126/science.aac4255
Source: PubMed